not tagged
not tagged
['axspa']
2022 asas-eular recommendations of axspa management
1) nsaids still first line
2) analgesics/opioids contraindicated 3) tnfi, il-17i first line bdmards, followed by jakinibs
4) tapering but not discontinuation of bdmards in sustained remission
abs#0542 #acr22 
Rheumatologist. Amateur chef. YNWA. Views and opinions are my own.